

## Centrose Announces Issuance of the Sixth CarboConnect<sup>®</sup> Related Patent



MADISON, WI. July 13, 2010 – Centrose LLC, a company focused on “making drugs better” through the use of novel targeting chemistry, announced today that the United States Patent and Trademark Office (USPTO) has issued yet another patent (7,754,874) that the company exclusively licensed through the Wisconsin Alumni Research Foundation (WARF). The patent entitled “Neoglycorandomization and Digitoxin Analogs” is the second major element of CarboConnect<sup>®</sup>.

The invention that led to issuance of this sixth patent in Centrose’s toolbox was discovered by UW-Madison Professor and Centrose co-founder Dr. Jon Thorson. The invention was initially funded by the National Institutes of Health and published in the prestigious journal *Proceeding of the National Academy of Sciences* in August of 2005. This is the second major element on the CarboConnect platform and allows for rapid enhancement of most any single drug into multiple new drug leads. Centrose has been using CarboConnect to explore how less toxic and more potent drugs can be created.

Recently, Centrose has been using CarboConnect to attach drugs onto targeting antibodies. The antibodies are used to drive the drugs to specific cell types. “We have recently discovered that our drugs can easily be coupled to antibodies using our novel sugar chemistry and this makes them behave in a very specific manner”, stated Dr. James Prudent, CEO and President of Centrose. “This latest patent is just another piece of what we believe to be an extremely valuable platform.”

Centrose now uses CarboConnect to not only enhance drugs, but to also target them to specific diseased cell types. The ease of which CarboConnect creates enhanced drug leads is now allowing Centrose to discover even more disease selective drugs.

### **About Centrose LLC**

Centrose delivers powerful technologies for the enhancement of therapeutics and utilizes these technologies to enhance anti-cancer and anti-infective drugs. Specifically, Centrose is attaching novel sugars and targeting molecules to enhance the pharmaceutical properties of drugs with established therapeutic potential. The Company uses the proprietary CarboConnect<sup>®</sup> system to enhance, screen and fine tune drug action. Centrose owns exclusive rights to drug enhancing technologies and continues to develop and patent new technologies and enhanced drugs. Centrose owns a broad set of patents and patent applications issued and filed by the Wisconsin Alumni Research Foundation and The Sloan Kettering Institute.

### **Contacts:**

James Prudent, Ph.D.  
President and CEO  
Centrose LLC  
(608) 209-8933